Trial Profile

A Phase 2, Open-Label Study of EZN-2208 (PEG-SN38) in Patients With Previously Treated Metastatic Breast Cancer (MBC).

Status: Discontinued

Phase of Trial: Phase II

Latest Information Update: 16 Feb 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Firtecan pegol (Primary)
Indications Advanced breast cancer
Focus Therapeutic Use

Most Recent Events

29 Jan 2022 Status changed from completed to discontinued.
02 Oct 2012 Planned End Date changed from 1 Sep 2012 to 1 Jun 2013 as reported by ClinicalTrials.gov record.
04 Jun 2012 Final results were reported at the Annual Meeting of the American Society of Clinical Oncology, and in an Enzon Pharmaceuticals media release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com